Quantcast

Latest Purdue Pharma L.P. Stories

2014-07-16 08:28:03

FDA also approves the use of two Butrans patches for dose adjustments in appropriate chronic pain patients STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. The Butrans Transdermal System is also...

2014-07-08 08:31:18

Anticipated FDA action set for October 2014 STAMFORD, Conn., July 8, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by...

2014-06-18 08:29:38

Agreement renews and expands partnership to drive continued business value from infrastructure and application operations SUNNYVALE, California, June 18, 2014 /PRNewswire/ -- HCL Technologies Ltd [http://www.hcltech.com ]. (HCL), a global IT services provider, today announced that its customer, Purdue Pharma L.P [http://www.purduepharma.com ], a leading pharmaceutical company has extended its end-to-end IT Infrastructure Management engagement with HCL, marking an important...

2014-05-27 12:31:59

LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Pain Management Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_pain_management_drugs_market_2014_2018.html TechNavio's analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The...

2014-05-22 08:28:50

STAMFORD, Conn., May 22, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that Saeed Motahari has joined the company as Senior Vice President and Chief Commercial Officer. "We welcome Saeed to the Purdue team. I am confident that his impressive capabilities will strengthen our organization," said Mark Timney, President and CEO of Purdue Pharma. "Saeed's experience and expertise make him uniquely qualified to lead our commercial efforts." Saeed has more than 20 years of...

2014-04-30 08:33:23

Data from Clinical Drug-liking Studies Also to be Presented at APS Today STAMFORD, Conn., April 30, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) seeking authorization to market a once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate...

2014-04-29 12:33:30

STAMFORD, Conn., April 29, 2014 /PRNewswire/ -- Purdue Pharma L.P. will present results from a number of research studies at the American Pain Society (APS) 33(rd) Annual Scientific Meeting, April 30-May 3, 2014, in Tampa, Fla. Following is a schedule of select poster presentations: Authors Date / Time Title...

2014-04-04 16:23:31

Review of published literature points to need for physician monitoring, awareness of patient overuse of acetaminophen STAMFORD, Conn., April 4, 2014 /PRNewswire/ -- A review of published medical literature has found that individuals who receive pain relievers containing acetaminophen are commonly prescribed doses close to or above the U.S. Food & Drug Administration's (FDA) recommended daily maximum dose (4g per day), putting them at increased risk of acetaminophen overdose and liver...

2014-03-12 08:30:24

Investigational Opioid Analgesic Incorporates Abuse-Deterrent Technology STAMFORD, Conn., March 12, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that a Phase 3 study of an investigational extended-release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low back pain treated with the once-daily analgesic agent experienced statistically significant reduction in pain compared with placebo (p=0.0016). This investigational...

2014-01-27 08:27:48

STAMFORD, Conn., Jan. 27, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that the company's Board of Directors has appointed Mark Timney as President and Chief Executive Officer. "We found a proven leader in Mark Timney," said Dr. Raymond Sackler, co-founder and board member of Purdue. "I am confident that his capabilities and experience, coupled with Purdue's culture of excellence, will grow our business and strengthen our healthcare industry leadership." Mark brings more...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related